BiotechTube

VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum

Phase 1/2Completed
1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Norovirus Infections

Conditions

Norovirus Infections

Trial Timeline

Dec 27, 2021 → Oct 27, 2023

NCT ID
NCT05212168

About VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum

VXA-G1.1-NN + Norovirus GI.1 Norwalk Virus Inoculum is a phase 1/2 stage product being developed by Vaxart for Norovirus Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT05212168. Target conditions include Norovirus Infections.

What happened to similar drugs?

0 of 1 similar drugs in Norovirus Infections were approved

Approved (0) Terminated (0) Active (1)
🔄mRNA-1403ModernaPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05212168Phase 1/2Completed

Competing Products

13 competing products in Norovirus Infections

See all competitors
ProductCompanyStageHype Score
mRNA-1403ModernaPhase 2
0
mRNA-1403ModernaPhase 3
0
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-G1.1-NN (high dose) Oral Vaccine Tablet + VXA-G1.1-NN (low dose) Oral Vaccine TabletVaxartPhase 1
19
VXA-G1.1-NN + VXA-G2.4-NS + VXA G1.1 NN-T + VXA G2.4 NS-TVaxartPhase 1
23
VXA-G1.1-NNVaxartPhase 1/2
22
VXA-G1.1-NN Oral VaccineVaxartPhase 1
19
VXA-G1.1-NNVaxartPhase 1
19
Norwalk GI.1 VirusVaxartPhase 1
19
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose + Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose + PlaceboVaxartPhase 2
25
VXA-G1.1-NN + VXA-G2.4-NS + Placebo TabletsVaxartPhase 1
19
VXA-GI.1.NN + Placebo TabletVaxartPhase 1
19
CDI-988 + PlaceboCocrystal PharmaPhase 1/2
29